-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BR-790 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BR-790 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BR-790 in Solid Tumor Drug Details: BR-790 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GL-0034 in Type 2 Diabetes
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GL-0034 in Type 2 Diabetes report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GL-0034 in Type 2 Diabetes Drug Details: GL-0034 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CT-0594CP CAR-T Cells in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CT-0594CP CAR-T Cells in Relapsed Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CT-0594CP CAR-T Cells in Relapsed Multiple Myeloma Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CT-0594CP CAR-T Cells in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CT-0594CP CAR-T Cells in Refractory Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CT-0594CP CAR-T Cells in Refractory Multiple Myeloma Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CT-0594CP CAR-T Cells in Plasma Cell Neoplasm
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CT-0594CP CAR-T Cells in Plasma Cell Neoplasm report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CT-0594CP CAR-T Cells in Plasma Cell Neoplasm Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CT-0594CP CAR-T Cells in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CT-0594CP CAR-T Cells in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CT-0594CP CAR-T Cells in Relapsed Multiple Myeloma Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CT-0594CP CAR-T Cells in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CT-0594CP CAR-T Cells in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CT-0594CP CAR-T Cells in Refractory Multiple Myeloma Drug Details:...
-
Product Insights
NewPlasma Cell Neoplasm – Drugs In Development, 2024
Empower your strategies with our Plasma Cell Neoplasm – Drugs In Development, 2024 report and make more profitable business decisions. Plasma Cell Neoplasm or plasma cell cancer is a group of diseases involving B-cells. These tumors are found in soft tissues that can be malignant or benign. Multiple Myeloma, lymphoplasmacytic lymphoma, plasmacytoma are the types of plasma cell cancers. Of all three multiple Myeloma is the most common and aggressive form. Age, chronic infection, exposure to radiation, hereditary factors, are some...
-
Product Insights
NewGastroesophageal (GE) Junction Carcinomas – Drugs In Development, 2024
Empower your strategies with our Gastroesophageal (GE) Junction Carcinomas – Drugs In Development, 2024 report and make more profitable business decisions. Gastroesophageal (GE) junction carcinomas are malignancies occurring at the point where the esophagus meets the stomach. Typically classified as adenocarcinomas or squamous cell carcinomas, adenocarcinomas are more prevalent. Risk factors include chronic gastroesophageal reflux disease (GERD), obesity, and smoking. Symptoms often manifest in advanced stages, including difficulty swallowing, weight loss, and abdominal pain. Diagnosis involves endoscopic procedures and imaging studies....
-
Product Insights
NewNon-Small Cell Lung Carcinoma – Drugs In Development, 2024
Empower your strategies with our Non-Small Cell Lung Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Non-small cell lung carcinoma (NSCLC) is the most common type of lung cancer. “Non-small cell” refers to the way cancer cells look under a microscope. If the cells look small, the cancer is referred to as small cell lung cancer (SCLC). According to the American Cancer Society, about 80 to 85 percentTrusted Source of all lung carcinomas fall into the...